Written questions by Fortune.

Innovation and Technology, how much Government funding there was into vitamin B12 deficiency research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into stem cell research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into malaria vaccination research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into neural tube defect prevention research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into thalassaemia research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

If she will make an assessment of the adequacy of the accessibility of the Consultation on the merchant shipping (vessels in commercial use for sport or pleasure) regulations 2025, published on 4 December 2024.

The consultations on the Merchant Shipping (EPIRB and PLB Registration) Regulations 2025 and the Merchant Shipping (Vessels in Commercial use for Sport or Pleasure) Regulations 2025 are published on gov.uk in a variety of formats: the main consultation documents are published as an HTML webpage which allows document readers to read for the visually impaired. The draft Regulations, Code, M-Notices and De Minimus Assessments are, by their nature, lengthy and technical documents and as a result have been published as .pdf files to preserve formatting and technical content; however, these too are capable of being read by pdf readers for the visually impaired. The response documents are published as open document format (ODF) files that can be reviewed and edited in any word processing software such as Microsoft Word or similar. As well as publishing on gov.uk, links to the consultation documents were sent directly by email to a number of different stakeholders, industry representatives and member organisations and the devolved nations bringing this directly to their attention. This has subsequently then been shared with the wider membership of such organisations. There were also press releases from the Maritime and Coastguard Agency (MCA) highlighting the launch of these public consultations, and they were shared on multiple official MCA social media channels, which were then shared further by the respective followers. The MCA understand the importance of accessibility to public consultations such as these and take their responsibility for promulgating information very seriously. I believe the MCA have taken every step to ensure the documents shared are in an accessible format and have clearly signposted how the public can input to the consultation process.

If she will make an assessment of the adequacy of the accessibility of the consultation entitled Consultation on the merchant shipping (EPIRB and PLB registration) regulations 2025, published on 5 December 2024.

The consultations on the Merchant Shipping (EPIRB and PLB Registration) Regulations 2025 and the Merchant Shipping (Vessels in Commercial use for Sport or Pleasure) Regulations 2025 are published on gov.uk in a variety of formats: the main consultation documents are published as an HTML webpage which allows document readers to read for the visually impaired. The draft Regulations, Code, M-Notices and De Minimus Assessments are, by their nature, lengthy and technical documents and as a result have been published as .pdf files to preserve formatting and technical content; however, these too are capable of being read by pdf readers for the visually impaired. The response documents are published as open document format (ODF) files that can be reviewed and edited in any word processing software such as Microsoft Word or similar. As well as publishing on gov.uk, links to the consultation documents were sent directly by email to a number of different stakeholders, industry representatives and member organisations and the devolved nations bringing this directly to their attention. This has subsequently then been shared with the wider membership of such organisations. There were also press releases from the Maritime and Coastguard Agency (MCA) highlighting the launch of these public consultations, and they were shared on multiple official MCA social media channels, which were then shared further by the respective followers. The MCA understand the importance of accessibility to public consultations such as these and take their responsibility for promulgating information very seriously. I believe the MCA have taken every step to ensure the documents shared are in an accessible format and have clearly signposted how the public can input to the consultation process.

Innovation and Technology, how much Government funding there was into haemophilia research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Innovation and Technology, how much Government funding there was into human immunodeficiency disease research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR).UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally.UKRI delivers a substantial portfolio of researcher-led projects. This includes a wide variety of areas including physiological, biological and mechanistic aspects that are applicable to many diseases, disorders and other conditions.Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24Hodgkin LymphomaUKRI did not commit any funding for Hodgkin lymphoma research in 2023-24.NIHR has not allocated funding for research concerning Hodgkin Lymphoma during financial year 2023-24.Myelodysplastic SyndromeUKRI did not commit any new funding for Myelodysplastic Syndrome research in 2023-24.NIHR has not allocated funding for research concerning Myelodysplastic Syndrome during financial year 2023-24.Stem CellThe total commitment in 2023/24 from UKRI for research concerning Stem Cells was £63,966,085 for 69 awards (14 awards from BBSRC; 4 awards from EPSRC; 6 awards from Innovate UK; 27 awards from MRC with a value of £28,347,161; 3 awards from NC3Rs; 15 awards from centrally managed UKRI schemes).NIHR has not funded any research concerning Stem Cells during financial year 2023-24.HaemophiliaUKRI did not commit any new funding for Haemophilia research in 2023-24.NIHR allocated £154,000 for high-quality research concerning Haemophilia in 2023-24Sickle CellUKRI did not commit any new funding for Sickle Cell research in 2023-24.NIHR allocated £336,368 for high-quality research concerning Cickle Cell research in the financial year 2023-24ThalassaemiaUKRI did not commit any new funding for Thalassaemia research in 2023-24.NIHR allocated £158,900 for high-quality research concerning Thalassaemia in the financial year 2023-24Human Immunodeficiency DiseaseThe total commitment from UKRI in 2023/24 was £13,983,734 for 13 awards (1 award from EPSRC; 8 awards from MRC with a value of £10,800,617 for Human Immunodeficiency Virus (HIV) research; 4 awards from centrally managed UKRI schemes).NIHR allocated £5,620,876 for high quality research concerning Human Immunodeficiency Disease (HIV and AIDS) in 2023-24Vitamin B12 deficiencyThe total commitment across UKRI in 2023-24 for Vitamin B12 deficiency research was £470,348 for 2 awards from Innovate UK.NIHR has not allocated any funds concerning Vitamin B12 Deficiency during financial year 2023-24.Neural Tube Defect PreventionThe total commitment from UKRI in 2023/24 for research concerning Neural Tube Defect Prevention was £4,289,077 for 4 awards (2 awards from MRC with a value of £3,949,400; 1 award from ESRC; 1 award from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Neural Tube Defect Prevention research during the financial year of 2023-24.Malaria vaccinationThe total commitment from UKRI in 2023/24 for research concerning Malaria vaccination was £11,697,976 for 7 awards (2 awards from MRC with a value of £3,387,100; 5 awards from centrally managed UKRI schemes).NIHR has not allocated any funds concerning Malaria Vaccination research during the financial year of 2023-24. The NIHR Oxford Biomedical Research Centre supports the development and testing of malaria vaccines, such as the R21/Matrix-M malaria vaccine.

Communities and Local Government, if she will make an assessment of the adequacy of the accessibility of the consultation entitled Reforms to the Energy Performance of Buildings regime, published on 4 December 2024.

The Government published the consultation on reforms to the Energy Performance of Buildings regime via www.gov.uk and is content that it meets the expected accessibility standards to allow all interested parties to contribute their views. As prescribed in the Government’s Publishing Accessible Documents guidance, the consultation is published in HTML format to make it easier to read and to find.It provides alternative ways to respond to meet the range of accessibility needs; an online response option, a direct email address and a postal address for those unable to respond online. Anyone having any difficulty responding can get in touch using the contact details available to request assistance or an alternative way to respond. We also provide documents in alternative formats when these are requested by the public, including large print and braille. We have an alternative formats email address published on gov.uk which invites users to request a different format if they cannot use one of our documents (alternativeformats@communities.gov.uk).

Communities and Local Government, if she will make an assessment of the adequacy of the accessibility of the Consultation on introducing permitted insurance fees for landlords, freeholders and property managing agents, published on 2 December 2024.

The government published the consultation on introducing permitted insurance fees for landlords, freeholders and property managing agents via gov.uk and is content that it meets the expected accessibility standards to allow all interested parties to contribute their views.As prescribed in the government’s Publishing Accessible Documents guidance, the consultation is published in HTML format to make it easier to read and to find. The guidance in question provides alternate ways to respond to meet the range of accessibility needs, including an online response option and via direct email address. Anyone having any difficulty responding can get in touch using the contact details available to request assistance or an alternative way to respond. We also provide documents in alternative formats when these are requested by the public, including large print and braille. We have an alternative formats email address published on gov.uk which invites users to request a different format if they cannot use one of our documents (alternativeformats@communities.gov.uk).

Innovation and Technology, how much Government funding there was into ankylosing spondylitis research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into crystal arthropathy research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into systemic lupus erythematosus research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into stills disease research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into lyme disease research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into rheumatoid arthritis research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into fibromyalgia research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government funding there was into osteoarthritis arthritis research in 2023-24; and which public bodies provided that funding.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.

Innovation and Technology, how much Government investment into multiple myeloma there was in 2023-24; and which public bodies provided that investment.

DSIT funds medical research through UK Research and Innovation (UKRI) and the Department of Health and Social Care funds research through the National Institute for Health and Care Research (NIHR). UKRI’s Medical Research Council (MRC) supports the best scientific research to improve human health, with work ranging from molecular level science to public health medicine. MRC plays a key role in funding underpinning research which may not be attributable to a specific disease but will benefit medical research more generally. As part of this, UKRI funds research on immunology which is relevant to all of these diseases and will not be categorised per disease. Details of UKRI and NIHR funding on specific areas is provided in the table below: UKRI funding committed in 2023 and 2024 to dateNIHR funding in FY 2023/24rheumatoid arthritisThe total commitment for research concerning rheumatoid arthritis from UKRI was £7,640,156 for 10 awards (2 awards from Innovate UK; 1 award from EPSRC; 7 awards from MRC with a value of £6,260,577).NIHR allocated £3,063,380 for research concerning rheumatoid arthritis in F/Y 2023-24.osteoarthritisThe total commitment from for research concerning osteoarthritis from UKRI was £8,136,483 for 15 awards (6 awards from Innovate UK; 1 award from BBSRC; 2 awards from EPSRC; 1 award from ESRC; 3 awards from MRC with a value of £1,503,711; 2 awards from NC3Rs).NIHR allocated £2,388,275 for research concerning osteoarthritis in F/Y 2023-24.psoriatic arthritisThe total commitment for research concerning psoriatic arthritis from UKRI was £500,965 for 1 award (Innovate UK).NIHR allocated £154,496 for research concerning psoriatic arthritis in F/Y 2023-24.systemic lupus erythematosusThe total commitment for research concerning systemic lupus erythematosus from UKRI was £3,673,302 for 3 awards (1 award from Innovate UK; 1 award from EPSRC; 1 award from MRC with a value of £1,636,608)The NIHR spent £155,574 on systemic lupus erythematosus research in F/Y 2023-24.joint replacementThe total commitment for research concerning joint replacement from UKRI was £4,736,426 for 5 awards (3 awards from Innovate UK; 2 awards from EPSRC).The NIHR spent £4,208,220 on joint replacement research in F/Y 2023-24.crystal arthropathyUKRI did not commit any funding specifically for crystal arthropathy research in 2023 and 2024 to date.The NIHR spent £2,061,659 on crystal arthropathy research in F/Y 2023-24.osteoporosisThe total commitment from for research concerning osteoporosis from UKRI was £2,363,661 for 6 awards (4 awards from Innovate UK; 1 award from BBSRC; 1 award from ESRC).NIHR allocated £379,475 for research concerning osteoporosis in F/Y.compression fractureUKRI did not commit any funding specifically for compression fracture research in 2023 and 2024 to date.NIHR has not funded any research concerning compression fracture during F/Y 2023-24.multiple myelomaUKRI did not commit any funding specifically for multiple myeloma research in 2023 and 2024 to dateNIHR allocated £416,500 for research concerning multiple myeloma in F/Y 2023-24.vitamin D deficiency diseaseThe total commitment for research concerning vitamin D deficiency disease from UKRI was £261,394 for 2 awards (Innovate UK).NIHR has not allocated funds concerning Vitamin D deficiency disease research during F/Y 2023-24.osteomalaciaUKRI did not commit any funding specifically for osteomalacia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning osteomalacia disease research during F/Y 2023-24FibromyalgiaUKRI did not commit any funding specifically for fibromyalgia research in 2023 and 2024 to date.NIHR has not allocated any funds concerning fibromyalgia disease during F/Y 2023-24.ankylosing spondylitisUKRI did not commit any research specifically for ankylosing spondylitis research in 2023 and 2024 to date.NIHR allocated £199,500 for research concerning ankylosing spondylitis in F/Y 2023-24.stills diseaseUKRI did not commit any research specifically for stills disease research in 2023 and 2024 to date.NIHR has not funded any research concerning stills disease during F/Y 2023-24.lyme diseaseThe total commitment for research concerning lyme disease from UKRI was £1,259,602 for 1 award (BBSRC).NIHR has not funded any research concerning lyme disease during F/Y 2023-24reactive arthritisUKRI did not commit any funding specifically for reactive arthritis research in 2023 and 2024 to date.The NIHR has not funded any research concerning reactive arthritis during F/Y 2023-24.